openPR Logo
Press release

Are we Getting Closer to a New Class of Antibiotic? DeNovaMed Explain more in an Exclusive New Interview

07-31-2017 11:31 PM CET | Health & Medicine

Press release from: SMi Group

DeNovaMed New Interview

DeNovaMed New Interview

SMi Group release a new interview with DeNovaMed Ahead of their Keynote Address at American Superbugs Summit

SMi Group are thrilled to welcome the expertise of Christopher McMaster when he presents an exclusive keynote address at Superbugs USA 2017 this fall. Dr McMaster is the President & CEO of DeNovaMed, a Halifax based biotech that specialises in the development of a new class of antibiotics.

The presentation will offer insight into computer aided drug design and synthesis to ensure a library of small molecules with structures unlike any other known antibiotic versus a novel target.

To date DeNovaMed have synthesized over 650 novel compounds with increasing potency. Efficacy in animal models and preclinical PK/ADME of lead compounds suggest that DeNovaMed should be able to proceed to a first in human trial with their new antibiotic class pending further studies.

In the run-up to the event, SMi Group caught up with Christopher McMaster to discuss common industry hurdles and clinical progress. From the answers provided, it is apparent that a lack of antibiotic funding is still the most common pitfall in the development of new antibiotics.

“To be honest it all comes down to money, sorry to say. It is odd that a new cancer drug that can extend a life by 3-6 months can sell for $250,000 for those 6 months of treatment, and yet a new antibiotic that could save a life seems to not be able to have a similar price point. Either the price point for new antibiotics needs to be higher, or up-front incentives need to be in place to enable a cost structure that would enable bringing new antibiotics into the market realistic. The other option is for governments to get into the antibiotic preclinical and clinical trial business and move antibiotic development out of the private domain, however that is highly unlikely.” Christopher McMaster, President & CEO, DeNovaMed

The full interview in available to read in the event download center at
http://www.smi-online.co.uk/goto/2017superbugsusa.asp#tab_downloads

Other notable speakers on the agenda will include representatives from: Janssen, BARDA, CARB-X, Pfizer, MedImmune, Visterra, Contrafect, Centauri Therapeutics, UNT Health Science Center , Microbiotix and Merck.

A detailed program and full speaker line-up is available at www.superbugs-usa.com/openpr

Superbugs & Superdrugs USA will take place on 13th & 14th November at the Renaissance Woodbrigde Hotel in Iselin, New Jersey. Sponsored by Merck and Soligenix.

---end ---

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Contact Information:

For all media inquiries contact Teri Arri on Tel: +44 (0)20 7827 6162 / Email: tarri@smi-online.co.uk

Address:

SMi Group Ltd
Ground & First Floor
1 Westminster Bridge Road
London, SE1 7XW

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Are we Getting Closer to a New Class of Antibiotic? DeNovaMed Explain more in an Exclusive New Interview here

News-ID: 649171 • Views:

More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Conference
Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation. Industry leaders will uncover the
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual Highly Potent Active Pharmaceutical Ingredients Conference.
Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK. With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference in Boston, USA
FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022. With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week. With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman. The

All 5 Releases


More Releases for DeNovaMed

Antibiotic Drug Experts + Senior Industry Leaders set to Gather at Superbugs USA
SMi Group will open doors in 3 weeks to host the next annual USA Superbugs summit when it returns to Iselin, New Jersey on Nov 13th – 14th. http://www.superbugs-usa.com/opr Following over two decades of expertise in Europe, the USA show will gather senior industry experts to delve deeper into core issues surrounding government funding and initiatives, breakthroughs in drug discovery, strategies to strengthen the antibiotic pipeline and resistance prevention. Highlights will include
How is the Medical Industry Still Trying to Overcome Antibacterial Resistance?
Too few new antibiotics are under development to combat the threat of multidrug-resistant infections, according to a new World Health Organization report published in recent weeks. Adding to the concern, it is likely that the speed of increasing resistance will outpace the slow drug development process. * Source: http://ti.me/2wMC47B SMi’s Superbugs and Superdrugs USA conference will address these challenges and provide further insight into financing initiatives and industry incentives to increase
A Spotlight on Industry Incentives for New Superdrugs
Following on from the growing pressure to develop new antibiotics, SMi’s 19th annual Superbugs & Superdrug’s conference will return to Central London in just under three weeks’ time with a dedicated spotlight on industry incentives. Using a criteria which examines how deadly the bacteria is and whether new antibiotics to treat them are already in the pipeline, the World Health Organisation (WHO) recently released a list of drug resistant "priority pathogens"
Attendee List Released for Superbugs 2017 Featuring FDA, GSK, MHRA, Merck and Ab …
With just 4 weeks to go, an attendee list featuring an international audience of AMR experts and scientific pioneers has been released ahead of SMi's long running 19th annual summit on Superbugs & Superdrugs. The industry calendar highlight on antibiotic resistance will provide a platform for attendee's to network, exchange novel solutions and consolidate current strategy. Notable sessions on the agenda include: 1. Guidance on common governing pitfalls presented by the FDA. 2. Strategies to